ZIMV Stock Recent News

Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per share Net Sales from Continuing Operations of $116.7 million Net Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA [1] from Continuing Operations of $17.5 million; Adjusted EBITDA [1] margin of 15.0% GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS [1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025.

PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025.

PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ZimVie Inc. (NasdaqGS: ZIMV) to an affiliate of ARCHIMED. Under the terms of the proposed transaction, shareholders of ZimVie will receive $19.00 in cash for each share of ZimVie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, o.

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating ZimVie Inc. (NASDAQ: ZIMV ) related to its sale to an affiliate of ARCHIMED. Under the terms of the proposed transaction, ZimVie shareholders will receive $19.00 in cash per share. Is it a fair deal?

MILWAUKEE , July 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating ZimVie (NASDAQ: ZIMV) for possible breaches of fiduciary duty and other violations of law in its transaction with ARCHIMED. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ZimVie Inc. (NASDAQ: ZIMV) to an affiliate of ARCHIMED for $19.00 in cash per share is fair to ZimVie shareholders. Halper Sadeh encourages ZimVie shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether ZimVie and its.

PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries.

ZimVie's stock has plunged over 40% since my downgrade, but recent cost reductions are improving profitability, and the stock is forming a bottoming pattern. Despite continued revenue declines, especially internationally, EBITDA margins have expanded and full-year guidance remains achievable. Valuation is now attractive, with ZIMV trading at a significant discount to dental implant peers on a Fwd EV/EBITDA basis.